Results 181 to 190 of about 550,507 (355)

Cyclin-Dependent Kinases [PDF]

, 2011
openaire   +1 more source

Cyclin-Dependent Kinase [PDF]

, 2020
openaire   +1 more source

Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitor

British Journal of Pharmacology, 2014
T. Albert, C. Rigault, J. Eickhoff, K. Baumgart, Claudia Antrecht, B. Klebl, Gerhard Mittler, M. Meisterernst   +7 more
semanticscholar   +1 more source

Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR‐positive/HER2‐negative metastatic breast cancer: Real‐world data from the OPAL registry

International Journal of Cancer, EarlyView.
What's New? Balancing efficacy and tolerability is challenging in oncology, as standard dosing often prioritizes maximum tolerated doses over other patient needs. Here, the authors developed a predictive index to identify patients with increased probability of dose reduction in metastatic breast cancer and compared the real‐world effectiveness of ...
Patrick Marschner, Kai Ringwald, Marc Thill, Mark‐Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser‐Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group   +19 more
wiley   +1 more source

Multidisciplinary Strategies for Targeting Tumor Dormancy in Breast Cancer Therapeutics: Hallmarks, Mechanism, and Approaches

iMetaMed, EarlyView.
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen, Hui Chen, Vijaya Raghavan, Jing Huang, Jin Wang   +4 more
wiley   +1 more source

Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events. [PDF]

PLoS One
Zhang S, Zhang R, Xia Y, Cao D.
europepmc   +1 more source

Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.

Proceedings of the National Academy of Sciences of the United States of America, 1996
Alcorta Da, Y. Xiong, Dale L. Phelps, G. Hannon, D. Beach, Barrett Jc   +5 more
semanticscholar   +1 more source

Holistic bone developing microenvironment engineered apoptotic extracellular vesicles recapitulate multidimensional developmental signatures in adult and senile bone repair

Interdisciplinary Medicine, EarlyView.
The developing bone was identified as an M2a‐like macrophage driven immune microenvironment with multidimensional developmental signatures. hME‐ApoEVs were successfully fabricated via stimulating the M2a‐like developing microenvironment in vitro and confirmed its recapitulation of developmental features.
Xiaoran Yu, Jieyun Xu, Yuan Zhao, Xinyu Guo, Hongcheng Chen, Junlong Xue, Yong Ao, Linjun Zhang, Xiaomeng Gao, Xueli Mao, Songtao Shi, Zetao Chen   +11 more
wiley   +1 more source

Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors. [PDF]

BMC Cancer
Kubeczko M, Polakiewicz-Gilowska A, Świderska K, Mianowska-Malec M, Leśniak A, Łanoszka B, Chomik K, Grandys B, Lisovska N, Woźniak G, Latusek T, Stobiecka E, Simek J, Pyciński B, Bobek-Billewicz B, Chmielik E, Jarząb M.   +16 more
europepmc   +1 more source

Engineered extracellular vesicles for precision renal therapy: Bioengineering strategies and clinical translation

Interdisciplinary Medicine, EarlyView.
Engineered extracellular vesicles (EVs) offer a versatile platform for kidney‐targeted therapy. This review summarizes bioengineering strategies, including cargo loading, surface modification, biomimetic fabrication, and biomaterial integration. We highlight translational challenges and propose future solutions to accelerate the clinical application of
Linru Shi, Bei Li, Wanzhu Liu, Haifeng Wu, Wenrong Xu, Cheng Ji, Hui Qian   +6 more
wiley   +1 more source